about
Calprotectin--a novel marker of obesity.Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes.Searching for the exercise factor: is IL-6 a candidate?Plasma and muscle myostatin in relation to type 2 diabetes.Satellite cells derived from obese humans with type 2 diabetes and differentiated into myocytes in vitro exhibit abnormal response to IL-6.Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans.The metabolic role of IL-6 produced during exercise: is IL-6 an exercise factor?Fat-specific protein 27 regulates storage of triacylglycerolRole of myokines in exercise and metabolism.Physiological roles of muscle-derived interleukin-6 in response to exercise.Plasma YKL-40: a BMI-independent marker of type 2 diabetes.Interleukin-6 stimulates lipolysis and fat oxidation in humans.Endurance training enhances skeletal muscle interleukin-15 in human male subjects.Interleukin-6 markedly decreases skeletal muscle protein turnover and increases nonmuscle amino acid utilization in healthy individuals.Acute moderate elevation of TNF-alpha does not affect systemic and skeletal muscle protein turnover in healthy humans.Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration?Role of vitamin C and E supplementation on IL-6 in response to training.Antioxidant supplementation does not alter endurance training adaptation.Tumor necrosis factor-alpha modulates human in vivo lipolysis.RETRACTED: Interleukin-6 receptor expression in contracting human skeletal muscle: regulating role of IL-6.Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans.Beneficial health effects of exercise--the role of IL-6 as a myokine.Vitamin E isoform-specific inhibition of the exercise-induced heat shock protein 72 expression in humans.Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle.Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction.Endurance training reduces the contraction-induced interleukin-6 mRNA expression in human skeletal muscle.Skeletal muscle adaptation: training twice every second day vs. training once daily.Recombinant human interleukin-6 infusion during low-intensity exercise does not enhance whole body lipolysis or fat oxidation in humans.Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation.Glucose ingestion during endurance training does not alter adaptation.RBP-to-retinol ratio, but not total RBP, is elevated in patients with type 2 diabetes.Association between interleukin-15 and obesity: interleukin-15 as a potential regulator of fat mass.Associations between insulin resistance and TNF-alpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes.Brain-derived neurotrophic factor (BDNF) and type 2 diabetes.Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity.Calprotectin is released from human skeletal muscle tissue during exercise.PGC-1β is downregulated by training in human skeletal muscle: no effect of training twice every second day vs. once daily on expression of the PGC-1 familyEffect of exercise, training, and glycogen availability on IL-6 receptor expression in human skeletal muscleInterleukin-6 Infusion During Human Endotoxaemia Inhibits In Vitro Release of the Urokinase Receptor from Peripheral Blood Mononuclear CellsEffect of antioxidant supplementation on insulin sensitivity in response to endurance exercise training
P50
Q33510158-35BF781D-E4AF-4987-8FBE-B6BAE10E2E57Q33762245-3F42ECA8-54A7-42EF-8135-6A214C18CFB1Q34275715-B2E71C1F-4933-4663-8C11-D5EC792FA59DQ34277885-04B7AF66-A235-4922-B4F0-16322A7A2B68Q34326387-AEDEE716-D771-4C81-A1E2-592C6227EB38Q34444458-223E66EA-8C2B-4397-9922-3DEA1646ED15Q35855943-184F9839-F7C8-4C8A-B7D7-7392540FA397Q36662761-691283CD-78FD-4633-BE12-E12E83A285F9Q36755279-E8A354A5-1AF2-40A6-8C36-D2595DB7D0EFQ36783595-6940B285-C6E6-4525-9AAA-6D72CECB2037Q36943769-77A7C630-D1FD-4DC3-A534-CC648B56DBDCQ42169595-A90DF7CB-C455-4626-AEBA-DB0A2B733BC4Q42263983-2D6AC3A8-AB2B-43DD-8A26-DD7D7E586609Q42435190-86B74886-9C7B-42A9-B806-B25164A7B939Q42443093-45215E0B-686F-4786-84DF-A62BFF6BB9E0Q42514046-A7BE081E-15EB-40EB-8035-1E54E0E1B58DQ42722646-2E506C08-2C17-4BAC-A83A-1E07D93529F1Q43216585-8F09E098-8449-43C9-8B80-0DB7A2BCFDD9Q43590617-E212C987-C223-4E9F-97D9-56837E4C9C0CQ44013866-391DDCC3-CB89-4C3F-9ACE-BBBBD2EACE75Q44364068-187E04D3-D2B9-4EF4-933D-94375C9E7F0AQ44816177-883FA324-3325-4CC6-9793-DB9B831E2EA9Q44834214-2ADB0617-7B95-42EB-9C93-8C9BEFF70009Q44915369-9045CA37-C943-4E5F-8992-754BDC3D2132Q44953893-A73536B8-EEA0-457D-8CC6-A900E913B525Q45013718-4377C790-0C83-4BF8-B24A-E8B8F1509855Q45054266-6E19AFA0-6BB5-458E-ADD0-F8C2D616D88BQ45291537-FB36F122-3D16-44E9-AA86-AC4B70F6E608Q45780173-4DFF222C-7CCB-40D1-B048-CE0227868FB1Q46116533-D3C33A97-2772-49FB-AE92-80EE60862AE8Q46122914-DBB5C300-8116-42E5-9DAE-0DC3BBAED16CQ46433459-C6C41485-F1B1-46B7-BC8A-5A7431F47E4BQ46956147-10499458-CB31-4E04-9772-CDA2F445CD64Q48345277-A17F0B22-F3FB-460B-A7F1-4E555F21BB1BQ51486562-582AF291-8202-4A2C-A1B1-A3FAB3236319Q53803699-BCAC4AEB-50DC-4320-B766-ECA5A0740629Q56240274-E4C7B140-B288-4D4C-A3AD-C3D4CBB77A17Q56240276-41C950EF-3BD7-4F90-8973-B32C7BFC6665Q56240277-D30A0D30-3B2E-4448-A8A3-10AE5E9DF930Q58171920-301BA86A-9809-4FB0-9756-F0525D23A9C0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christian P. Fischer
@ast
Christian P. Fischer
@en
Christian P. Fischer
@es
Christian P. Fischer
@nl
Christian P. Fischer
@sl
type
label
Christian P. Fischer
@ast
Christian P. Fischer
@en
Christian P. Fischer
@es
Christian P. Fischer
@nl
Christian P. Fischer
@sl
altLabel
Christian Philip Fischer
@en
prefLabel
Christian P. Fischer
@ast
Christian P. Fischer
@en
Christian P. Fischer
@es
Christian P. Fischer
@nl
Christian P. Fischer
@sl
P106
P1153
7402486409
P21
P31
P496
0000-0002-0657-9143